Identificación de potenciales blancos moleculares e inhibidores para el tratamiento de infecciones fúngicas con base en similitudes estructurales con proteínas del farmacoloma humano
| dc.audience | Comunidad Universidad de Medellín | |
| dc.contributor.advisor | Moreno Frías, Ernesto | |
| dc.contributor.advisor | Rubio Carrasquilla, Marcela | |
| dc.contributor.author | Bedoya Cardona, Johann Evelio | |
| dc.coverage.spatial | Lat: 06 15 00 N degrees minutes Lat: 6.2500 decimal degreesLong: 075 36 00 W degrees minutes Long: -75.6000 decimal degrees | |
| dc.date | 2026-03-12 | |
| dc.date.accessioned | 2026-04-13T15:24:47Z | |
| dc.description | Esta investigación tuvo como objetivo identificar nuevos blancos terapéuticos y compuestos antifúngicos mediante una estrategia combinada de análisis computacional y ensayos experimentales, tomando como referencia las proteínas del farmacoloma humano. Este “farmacoloma” corresponde al conjunto de productos génicos humanos modulados por fármacos aprobados. Se exploraron dos enfoques principales: el reposicionamiento de fármacos (uso de medicamentos ya aprobados para nuevas indicaciones), y el cribado virtual (virtual screening) de proteínas fúngicas específicas como posibles blancos moleculares. En una primera etapa se seleccionaron proteínas del farmacoloma humano con información cristalográfica disponible. A través de análisis estructurales y de secuencia se caracterizaron sus sitios de unión, identificando los aminoácidos clave en las interacciones proteína-ligando. Este conjunto se comparó con proteomas completos de hongos patógenos de alta prioridad definidos por la Organización Mundial de la Salud, incluyendo Candida albicans, Aspergillus fumigatus, Histoplasma capsulatum y Fusarium oxysporum. Se identificaron múltiples proteínas con potencial terapéutico, basadas en la conservación de sus sitios activos. Posteriormente, se generaron modelos computacionales de proteínas fúngicas ortólogas (homólogas en diferentes especies) para evaluar la posible unión de inhibidores conocidos de proteínas humanas y detectar diferencias estructurales que permitan diseñar inhibidores específicos. Como modelo experimental se seleccionó H. capsulatum, agente causal de la histoplasmosis, enfermedad endémica en América y Colombia. Asimismo, se analizó la proteína MEK1 humana y sus ortólogos en H. capsulatum y F. oxysporum. Este último es responsable de la fusariosis, segunda causa de infecciones por mohos en humanos, cuya incidencia ha aumentado en los últimos años. | spa |
| dc.description | This research aimed to identify new therapeutic targets and antifungal compounds through a combined strategy of computational analysis and experimental assays, using the proteins of the human pharmacolome as reference. This human pharmacolome corresponds to the curated set of human gene products modulated by approved drugs. Two main approaches were explored: drug repurposing (using already approved medications for new indications), and virtual screening of specific fungal proteins as potential molecular targets. In the first stage, pharmacolome proteins with available crystallographic information were selected. Structural and sequence analyses were performed to characterize their binding sites, identifying key amino acids involved in protein–ligand interactions. This curated set was compared against complete proteomes of high-priority pathogenic fungi defined by the World Health Organization, including Candida albicans, Aspergillus fumigatus, Histoplasma capsulatum, and Fusarium oxysporum. Several proteins with therapeutic potential were identified based on the conservation of their active sites. Subsequently, computational models of fungal orthologs (homologous proteins across species) were generated to evaluate the possible binding of known inhibitors of human proteins and to detect structural differences that could enable the design of specific inhibitors. H. capsulatum was selected as the experimental model, as it is the causative agent of histoplasmosis, an endemic disease in the Americas and Colombia. In addition, the human protein MEK1 and its orthologs in H. capsulatum and F. oxysporum were analyzed. The latter is responsible for fusariosis, the second leading cause of mold infections in humans, whose incidence has significantly increased in recent years. | en |
| dc.description.degreelevel | Doctorado | |
| dc.description.degreename | Doctor en Modelación y Ciencia Computacional | |
| dc.format.extent | p. 1-73 | |
| dc.format.medium | Electrónico | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.other | T 0730 2025 | |
| dc.identifier.uri | https://repository.udemedellin.edu.co/handle/11407/9292 | |
| dc.language.iso | spa | |
| dc.publisher.faculty | Facultad de Ciencias Básicas | |
| dc.publisher.place | Medellín | |
| dc.publisher.program | Doctorado en Modelación y Ciencia Computacional | |
| dc.relation.citationendpage | 73 | |
| dc.relation.citationstartpage | 1 | |
| dc.relation.references | Albataineh, M. T., Sutton, D. A., Fothergill, A. W., & Wiederhold, N. P. (2016). Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance. Infectious Disease Clinics of North America, 30(1), 13–35. https://doi.org/10.1016/J.IDC.2015.10.014 | |
| dc.relation.references | Alvarez-Moreno, C. A., Cortes, J. A., & Denning, D. W. (2018). Burden of fungal infections in Colombia. Journal of Fungi, 4(2). https://doi.org/10.3390/JOF4020041 | |
| dc.relation.references | Armstrong, P. A., Rivera, S. M., Escandon, P., Caceres, D. H., Chow, N., Stuckey, M. J., Díaz, J., Gomez, A., Vélez, N., Espinosa-Bode, A., Salcedo, S., Marin, A., Berrio, I., Varón, C., Guzman, A., Pérez-Franco, J. E., Escobar, J. D., Villalobos, N., Correa, J. M., … Pacheco, O. (2019). Hospital-Associated Multicenter Outbreak of Emerging Fungus Candida auris, Colombia, 2016. Emerging Infectious Diseases, 25(7), 1339. https://doi.org/10.3201/EID2507.180491 | |
| dc.relation.references | Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery, 3(8), 673–683. https://doi.org/10.1038/nrd1468 | |
| dc.relation.references | Branda, F., Petrosillo, N., Ceccarelli, G., Giovanetti, M., De Vito, A., Madeddu, G., Scarpa, F., & Ciccozzi, M. (2025). Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives. Infectious Disease Reports, 17(4), 91. https://doi.org/10.3390/idr17040091 | |
| dc.relation.references | Caceres, D. H., Echeverri Tirado, L. C., Bonifaz, A., Adenis, A., Gomez, B. L., Flores, C. L. B., Canteros, C. E., Santos, D. W., Arathoon, E., Soto, E. R., Queiroz‐Telles, F., Schwartz, I. S., Zurita, J., Damasceno, L. S., Garcia, N., Fernandez, N. B., Chincha, O., Araujo, P., Rabagliati, R., … Giusiano, G. (2022). Current situation of endemic mycosis in the Americas and the Caribbean: Proceedings of the first international meeting on endemic mycoses of the Americas ( <scp>IMEMA</scp> ). Mycoses, 65(12), 1179–1187. https://doi.org/10.1111/myc.13510 | |
| dc.relation.references | Campoy, S., & Adrio, J. L. (2017). Antifungals. In Biochemical Pharmacology (Vol. 133, pp. 86–96). Elsevier Inc. https://doi.org/10.1016/j.bcp.2016.11.019 | |
| dc.relation.references | Chavez-Dozal, A. A., Lown, L., Jahng, M., Walraven, C. J., & Lee, S. A. (2014). In vitro Analysis of Finasteride Activity against Candida albicans Urinary Biofilm Formation and Filamentation. Antimicrobial Agents and Chemotherapy, 58(10), 5855–5862. https://doi.org/10.1128/AAC.03137-14 | |
| dc.relation.references | Dao, A., Kim, H. Y., Halliday, C. L., Oladele, R., Rickerts, V., Govender MMed, N. P., Shin, J.- H., Heim, J., Ford, N. P., Nahrgang, S. A., Gigante, V., Beardsley, J., Sati, H., Morrissey, C. O., Alffenaar, J.-W., & Alastruey-Izquierdo, A. (2024). Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list. Medical Mycology, 62(6). https://doi.org/10.1093/mmy/myae039 | |
| dc.relation.references | Denning, D. W. (2002). Echinocandins: A new class of antifungal. Journal of Antimicrobial Chemotherapy, 49(6), 889–891. https://doi.org/10.1093/jac/dkf045 | |
| dc.relation.references | Denning, D. W. (2024). Global incidence and mortality of severe fungal disease. In The Lancet Infectious Diseases (Vol. 24, Issue 7, pp. e428–e438). Elsevier Ltd. https://doi.org/10.1016/S1473-3099(23)00692-8 | |
| dc.relation.references | Fang, W., Wu, J., Cheng, M., Zhu, X., Du, M., Chen, C., Liao, W., Zhi, K., & Pan, W. (2023). Diagnosis of invasive fungal infections: challenges and recent developments. In Journal of Biomedical Science (Vol. 30, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12929-023-00926-2 | |
| dc.relation.references | Gintjee, T. J., Donnelley, M. A., & Thompson, G. R. (2020). Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. Journal of Fungi, 6(1), 28. https://doi.org/10.3390/jof6010028 | |
| dc.relation.references | Giusiano, G. (2025). Systemic endemic mycoses: From a geographical risk to a concern expansion. Revista Iberoamericana de Micología. https://doi.org/10.1016/J.RIAM.2025.07.001 | |
| dc.relation.references | Greener, M. (2022). Why have we neglected fungal infections? Prescriber, 33(8–9), 20–23. https://doi.org/10.1002/psb.2008 | |
| dc.relation.references | Hazen, E. L., & Brown, R. (1951). Fungicidin, an Antibiotic Produced by a Soil Actinomycete. Experimental Biology and Medicine, 76(1), 93–97. https://doi.org/10.3181/00379727-76-18397 | |
| dc.relation.references | Kadariswantiningsih, I., Empitu, M., Santosa, T., & Alimu, Y. (2025). Antifungal resistance: Emerging mechanisms and implications (Review). Molecular Medicine Reports, 32(3), 1–17. https://doi.org/10.3892/mmr.2025.13612 | |
| dc.relation.references | Kapoor, M., Moloney, M., Soltow, Q. A., Pillar, C. M., & Shaw, K. J. (2020). Evaluation of resistance development to the GWT1 inhibitor manogepix (APX001A) in Candida species. Antimicrobial Agents and Chemotherapy, 64(1). https://doi.org/10.1128/AAC.01387-19/SUPPL_FILE/AAC.01387-19-S0001.PDF | |
| dc.relation.references | Kim, J. H., Cheng, L. W., Chan, K. L., Tam, C. C., Mahoney, N., Friedman, M., Shilman, M. M., & Land, K. M. (2020). Antifungal drug repurposing. Antibiotics, 9(11), 1–29. https://doi.org/10.3390/antibiotics9110812 | |
| dc.relation.references | Kim, K., Zilbermintz, L., & Martchenko, M. (2015). Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans. Annals of Clinical Microbiology and Antimicrobials, 14(1), 1–11. https://doi.org/10.1186/s12941-015-0090-4 | |
| dc.relation.references | Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009). Amphotericin B: side effects and toxicity. Revista Iberoamericana de Micologia, 26(4), 223–227.https://doi.org/10.1016/j.riam.2009.06.003 | |
| dc.relation.references | Li, D., Fan, S., Zhao, H., Song, J., Guo, L., Li, W., Xu, X., Li, Q., González-González, G. M., Xue, Y., Ayanlowo, O., & Guadalupe Frías De León, M. (2025). Worldwide trends and future projections of fungal skin disease burden: a comprehensive analysis from the Global Burden of Diseases study 2021. Front. Public Health, 13, 1580221. https://doi.org/10.3389/fpubh.2025.1580221 | |
| dc.relation.references | Maertens, J. A. (2004). History of the development of azole derivatives. Clinical Microbiology and Infection, 10, 1–10. https://doi.org/10.1111/j.1470-9465.2004.00841.x | |
| dc.relation.references | Man, M. A., Todea, D. A., Motoc, N. Ștefania, & Rajnoveanu, R.-M. (2023). Histoplasmosis: An Overview Treatment of Histoplasmosis. In E. Dantes & E. Dumea (Eds.), Histoplasmosis (p. Ch. 6). IntechOpen. https://doi.org/10.5772/intechopen.110365 | |
| dc.relation.references | MEJÍA-ARANGO, M. A., SANTA-VÉLEZ, C., CADAVID-SIERRA, M., VÉLEZ, L. M., COLMENARES, L. M., RESTREPO-JARAMILLO, B. N., & CARDONA-CASTRO, N. (2013). Estudio etiológico y epidemiológico de las micosis cutáneas en un laboratorio de referencia - Antioquia - Colombia. CES Medicina, 27, 7–19. | |
| dc.relation.references | Nasr Esfahani, A., Golestannejad, Z., Khozeimeh, F., Dehghan, P., Maheronnaghsh, M., & Zarei, Z. (2019). Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin. Medicine and Pharmacy Reports. https://doi.org/10.15386/mpr-1209 | |
| dc.relation.references | Nucci, F., Nouér, S. A., Capone, D., Anaissie, E., & Nucci, M. (2015). Fusariosis. Seminars in Respiratory and Critical Care Medicine, 36(5), 706–714. https://doi.org/10.1055/S-0035-1562897 | |
| dc.relation.references | Ordóñez, N., Tobón, A., Arango, M., Tabares, A., De Bedout, C., Gómez, B., Castañeda, E., & Restrepo, A. (1997). Brotes de histoplasmosis registrados en el área andina colombiana. Biomédica, 17(2), 105. https://doi.org/10.7705/biomedica.v17i2.941 | |
| dc.relation.references | Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2018). Drug repurposing: Progress, challenges and recommendations. In Nature Reviews Drug Discovery (Vol. 18, Issue 1, pp. 41–58). Nature Publishing Group. https://doi.org/10.1038/nrd.2018.168 | |
| dc.relation.references | Ramos-Ospina, N., Lambertinez-Álvarez, I. C., Hurtado-Bermúdez, L. J., Muñoz-Lombo, J. P., Vélez-Londoño, J. D., Valencia-Montagut, J. A., & Moncada-Vallejo, P. A. (2024). Management of disseminated histoplasmosis in a high-complexity clinic in Cali, Colombia. Medical Mycology, 62(7). https://doi.org/10.1093/MMY/MYAE058 | |
| dc.relation.references | Rios-Fabra, A., Moreno, A. R., & Isturiz, R. E. (1994). FUNGAL INFECTION IN LATIN AMERICAN COUNTRIES. Infectious Disease Clinics of North America, 8(1), 129–154. https://doi.org/10.1016/S0891-5520(20)30577-8 | |
| dc.relation.references | Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., & Overington, J. P. (2016). A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 16(1), 19–34. https://doi.org/10.1038/nrd.2016.230 | |
| dc.relation.references | Scully, M. C., & Baddley, J. W. (2018). Epidemiology of Histoplasmosis. Current Fungal Infection Reports, 12(1), 51–58. https://doi.org/10.1007/S12281-018-0309-X/METRICS | |
| dc.relation.references | Seagle, E. E., Williams, S. L., & Chiller, T. M. (2021). Recent Trends in the Epidemiology of Fungal Infections. In Infectious Disease Clinics of North America (Vol. 35, Issue 2, pp. 237–260). W.B. Saunders. https://doi.org/10.1016/j.idc.2021.03.001 | |
| dc.relation.references | Sigera, L. S. M., & Denning, D. W. (2023). Flucytosine and its clinical usage. Therapeutic Advances in Infectious Disease, 10. https://doi.org/10.1177/20499361231161387 | |
| dc.relation.references | Souza, C. M. de, Bezerra, B. T., Mellon, D. A., & de Oliveira, H. C. (2025). The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives. Current Research in Microbial Sciences, 8, 100341. https://doi.org/10.1016/j.crmicr.2025.100341 | |
| dc.relation.references | Tupaki-Sreepurna, A., & Kindo, A. J. (2018). Fusarium: The versatile pathogen. Indian Journal of Medical Microbiology, 36(1), 8–17. https://doi.org/10.4103/IJMM.IJMM_16_24 | |
| dc.relation.references | Valencia, Y., Cáceres, D. H., de Bedout, C., Cano, L. E., & Restrepo, Á. (2020). Frequency of Invasive Fungal Disease in Adults: Experience of a Specialized Laboratory in Medellín, Colombia (2009–2015). Journal of Fungi, 6(1), 39. https://doi.org/10.3390/jof6010039 | |
| dc.relation.references | Vanzolini, T., & Magnani, · Mauro. (2024). Old and new strategies in therapy and diagnosis against fungal infections. 108, 147. https://doi.org/10.1007/s00253-023-12884-8 | |
| dc.relation.references | Wall, G., Chaturvedi, A. K., Wormley, F. L., Wiederhold, N. P., Patterson, H. P., Patterson, T. F., & Lopez-Ribot, J. L. (2018). Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development. Antimicrobial Agents and Chemotherapy, 62(10). https://doi.org/10.1128/AAC.01084-18 | |
| dc.relation.references | Walsh, T. J., & Dixon, D. M. (1996). Spectrum of Mycoses. Medical Microbiology. https://www.ncbi.nlm.nih.gov/books/NBK7902/ | |
| dc.relation.references | Wishart, D. S. (2006). DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research, 34(90001), D668–D672. https://doi.org/10.1093/nar/gkj067 | |
| dc.relation.references | World Health Organization. (2022). WHO fungal priority pathogens list to guide research, development and public health action. | |
| dc.relation.references | World Health Organization. (2025a). Antifungal agents in development. https://www.who.int/observatories/global-observatory-on-health-research-anddevelopment/monitoring/antifungal-agents-in-development | |
| dc.relation.references | World Health Organization. (2025b). R&D funding for neglected diseases by disease. https://www.who.int/observatories/global-observatory-on-health-research-and development/monitoring/r-d-funding-flows-for-neglected-diseases-by-disease-year-andfunding-category | |
| dc.rights.accessrights | info:eurepo/semantics/openAccess | |
| dc.rights.creativecommons | Attribution-NonCommercial-ShareAlike 4.0 International | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0 | |
| dc.subject.lemb | Agentes antifungosos | |
| dc.subject.lemb | Biología molecular | |
| dc.subject.lemb | Fusarium oxysporum | |
| dc.subject.lemb | Hongos patógenos | |
| dc.subject.lemb | Micosis | |
| dc.subject.lemb | Nanotecnología | |
| dc.title | Identificación de potenciales blancos moleculares e inhibidores para el tratamiento de infecciones fúngicas con base en similitudes estructurales con proteínas del farmacoloma humano | spa |
| dc.type | info:eu-repo/semantics/doctoralThesis | |
| dc.type.coar | http://purl.org/coar/resource_type/c_db06 | |
| dc.type.hasversion | publishedVersion | |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | |
| dc.type.local | Tesis Doctoral |